Delcath Sys Inc (NASDAQ:DCTH)

CAPS Rating: 1 out of 5

The Company is a development stage Company.

Results 1 - 20 of 28 : 1 2 Next »

Recs

1
Member Avatar zzlangerhans (99.73) Submitted: 4/11/2014 11:25:40 PM : Underperform Start Price: $4.25 DCTH Score: +13.63

As long as Delcath is pinning their hopes on revenues from the Chemosat system, they're likely to be a dead stock walking. The recent reverse split may position them to raise more cash from dilution, but only a masochist would want to own the stock waiting for that to happen. Any bank or fund looking at the ugly picture Delcath has presented over the last three years is going to want a steep discount on the offering and is probably going to short the stock into it in order to juice their returns. Delcath calims that adoption of Chemosat is progressing in the UK and Germany, but they reported no revenue from Europe in the last quarter. A new clinical trial of Chemosat/Melblez in hepatocellular carcinoma probably won't begin enrolling patients until the second half of the year and Delcath is expecting to burn 5-6M/quarter this year. It's hard to see the company ever digging themselves out of this hole.

Recs

0
Member Avatar pchop123 (78.31) Submitted: 4/11/2014 1:48:57 PM : Underperform Start Price: $4.06 DCTH Score: +10.21

dropping faser than a rock

Recs

1
Member Avatar TSIF (99.96) Submitted: 4/10/2014 1:03:57 PM : Outperform Start Price: $3.95 DCTH Score: -6.07

This is an observation call, not a recommendation to "play" on CAPS.

Studying reverse splits, 1:16 yesterday resulted in a 20% additional selloff. Watched this a few other times and a rebound occurred. Working on theory about how people react to large reverse splits...usually run-up in advance, then drop after then up again....

Patterns are patterns until they are not....
NO FURTHER analysis on underlay. (not popular with zz, etc.).
Close = 7 Days if Green......

Recs

0
Member Avatar Angus2010 (< 20) Submitted: 4/29/2013 7:15:10 PM : Outperform Start Price: $1.20 DCTH Score: +194.64

Will pass FDA..

Recs

0
Member Avatar glenisintn (< 20) Submitted: 3/11/2013 6:18:08 PM : Outperform Start Price: $2.16 DCTH Score: +53.61

This stock will continue to grow will the anticipation of FDA approval.

Recs

0
Member Avatar patelk2 (< 20) Submitted: 2/25/2013 10:33:58 PM : Outperform Start Price: $1.51 DCTH Score: +123.19

PDUFA-date of June 14th. Run-up expected in May-2013. Expect run-up to $3.5+

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 7/4/2012 7:42:42 PM : Outperform Start Price: $1.74 DCTH Score: +78.79

Technical play

Recs

0
Member Avatar originalslang (< 20) Submitted: 1/13/2012 11:01:47 AM : Outperform Start Price: $4.29 DCTH Score: -57.88

upside potential unlimited when product benefits so many people and company is beaten down by the large drug companies. Delcath will be bought out by bms or pfizer in the near future

Recs

0
Member Avatar jgittes (< 20) Submitted: 11/27/2011 2:29:34 AM : Outperform Start Price: $2.23 DCTH Score: +16.51

outperform

Recs

2
Member Avatar TDRH (99.76) Submitted: 3/29/2011 11:56:15 AM : Outperform Start Price: $7.01 DCTH Score: -88.03

Cannot remember who I was following on this pick.

Recs

1
Member Avatar solanZRaider (< 20) Submitted: 3/22/2011 6:42:47 PM : Outperform Start Price: $6.78 DCTH Score: -89.40

Mark4124NH

Recs

1
Member Avatar searleg (36.31) Submitted: 3/4/2011 1:50:33 PM : Outperform Start Price: $6.42 DCTH Score: -83.30

The PHP system they are developing will pass FDA approval and become the standard of care for organ chemotherapy treatment.

Recs

1
Member Avatar ryansal (< 20) Submitted: 2/27/2011 11:52:17 AM : Outperform Start Price: $6.32 DCTH Score: -81.16

DCTH has a lot of cash for a development stage company. And unlike the run up in december to almost $12 per the NDA , this year they have exposure in Europe... could we then see a run up to $15-$16 before the next NDA in Sept 2011?? Something to think about...

Recs

0
Member Avatar Andreavich (< 20) Submitted: 2/23/2011 5:28:44 PM : Outperform Start Price: $6.26 DCTH Score: -82.67

Because the FDA did not squash the product but has unresolved questions about it that require clarification.

Recs

0
Member Avatar gstroube (43.06) Submitted: 2/20/2011 12:43:44 PM : Outperform Start Price: $6.90 DCTH Score: -85.81

Great tecnology

Recs

0
Member Avatar Mark4124NH (< 20) Submitted: 2/4/2011 10:06:17 PM : Outperform Start Price: $10.76 DCTH Score: -107.05

DCTH is awaiting NDA from the FDA. It has begun to run as a result and its chart looks extremely positive technically. They just disclosed a 5.08% Blackrock stake in FDA 13g filing. And if the CEO is correct with his believe of 15b market potential, this stock is worth many times its current value.

Recs

0
Member Avatar Crucible151 (< 20) Submitted: 1/1/2011 1:59:01 PM : Outperform Start Price: $9.87 DCTH Score: -109.21

FDA approval very optimistic.

Recs

0
Member Avatar dtannen (< 20) Submitted: 10/26/2010 6:27:48 PM : Outperform Start Price: $8.70 DCTH Score: -115.12

Delcath should get approval for melanoma mid-2011. The opportunity is much bigger for its PHP system though.

Recs

0
Member Avatar pjrmis (< 20) Submitted: 10/22/2010 11:49:12 AM : Outperform Start Price: $8.31 DCTH Score: -112.72

This is really a no brainer when you get past all of the rhetoric. They built a system that puts Chemo only into the organ/region with cancer instead of poisoning the whole patient.

Once approved by the FDA in 2011 I predict a $50 share price.

Recs

1
Member Avatar syazic (70.15) Submitted: 9/10/2010 12:32:38 PM : Outperform Start Price: $6.41 DCTH Score: -109.30

bottom

Results 1 - 20 of 28 : 1 2 Next »

Featured Broker Partners


Advertisement